Pipeline


ONCOLOGY
ARQ 197	C-Met Inhibitor	Daiichi Sankyo⁴ Kyowa Hakko⁵
ARQ 621	Eg5 Inhibitor
ARQ 761	E2F Pathway Activator
BRAF Kinase Inhibitor	BRAF Inhibition
FGFR Inhibitor	FGFR Inhibition
Non-ATP Competitive Kinase Inhibitors	Arqule Kinase Inhibitor Platform (AKIP^TM)	Daiichi Sankyo⁶
NON-ONCOLOGY ArQule has provided compounds to certain pharmaceutical companies that are pursuing development programs in different indications. As material information becomes available regarding the status of these programs, ArQule will provide updates through its press releases or filings. Portfolio Updated October 2009 ¹ Pre-GLP toxicology testing ² Post-initiation of GLP toxicology testing ³ Designation follows initation of first patient enrollment and dosing ⁴ U.S., Europe, South America and the rest of the world, excluding Japan and select Asian countries ⁵ Japan and select Asian countries ⁶ Two targets in oncology; other applications for additional collaborations under consideration